Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Summaries of opinion Remove Summaries of opinion filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Withdrawn applications (10) Apply Withdrawn applications filter Orphan designations (116) Apply Orphan designations filter Referrals (17) Apply Referrals filter

Product number

Patient safety

Yes (8) Apply Yes filter

Authorisation status

Authorised (331) Apply Authorised filter Refused (1) Apply Refused filter Withdrawn (44) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Opinion status

Positive (8) Apply Positive filter

Application type

Initial authorisation (1) Apply Initial authorisation filter Post-authorisation (7) Apply Post-authorisation filter

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (13) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (146) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (2) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (26) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (18) Apply Yes filter

Compliance procedure number

Medicine type

Additional monitoring Remove Additional monitoring filter Accelerated assessment (85) Apply Accelerated assessment filter Biosimilar (100) Apply Biosimilar filter Conditional approval (93) Apply Conditional approval filter Exceptional circumstances (64) Apply Exceptional circumstances filter Generic (300) Apply Generic filter Orphan medicine (282) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

611 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion Remove Summaries of opinion filter Direct healthcare professional communication Remove Direct healthcare professional communication filter

Categories Human Remove Human filter

Medicine type Additional monitoring Remove Additional monitoring filter

Sort by

List item

Human medicine European public assessment report (EPAR): Revlimid (updated)

lenalidomide, Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes
Date of authorisation: 14/06/2007, , Revision: 50, Authorised, Last updated: 19/09/2023
List item

Human medicine European public assessment report (EPAR): Veyvondi (updated)

vonicog alfa, von Willebrand Diseases
Date of authorisation: 31/08/2018, , Revision: 8, Authorised, Last updated: 19/09/2023
List item

Human medicine European public assessment report (EPAR): Litfulo (updated)

ritlecitinib tosilate, Alopecia Areata
Date of authorisation: 15/09/2023, , Authorised, Last updated: 18/09/2023
List item

Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) (updated)

Chenodeoxycholic acid, Xanthomatosis, Cerebrotendinous; Metabolism, Inborn Errors
Date of authorisation: 10/04/2017, , , , Revision: 6, Authorised, Last updated: 18/09/2023
List item

Human medicine European public assessment report (EPAR): Jinarc (updated)

Tolvaptan, Polycystic Kidney, Autosomal Dominant
Date of authorisation: 27/05/2015, , Revision: 20, Authorised, Last updated: 18/09/2023
List item

Human medicine European public assessment report (EPAR): GHRYVELIN (previously Macimorelin Aeterna Zentaris) (updated)

macimorelin acetate, Diagnostic Techniques, Endocrine
Date of authorisation: 11/01/2019, , Revision: 3, Authorised, Last updated: 18/09/2023
List item

Human medicine European public assessment report (EPAR): Ranivisio (updated)

ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 25/08/2022, , , Revision: 3, Authorised, Last updated: 18/09/2023
List item

Human medicine European public assessment report (EPAR): Mepsevii (updated)

vestronidase alfa, Mucopolysaccharidosis VII
Date of authorisation: 23/08/2018, , , , Revision: 7, Authorised, Last updated: 14/09/2023
List item

Human medicine European public assessment report (EPAR): Neparvis (updated)

sacubitril, valsartan, Heart Failure
Date of authorisation: 26/05/2016, , Revision: 18, Authorised, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Xevudy (updated)

Sotrovimab, COVID-19 virus infection
Date of authorisation: 17/12/2021, , Revision: 9, Authorised, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Beovu (updated)

brolucizumab, Wet Macular Degeneration
Date of authorisation: 13/02/2020, , Revision: 10, Authorised, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene) (updated)

Pomalidomide, Multiple Myeloma
Date of authorisation: 05/08/2013, , Revision: 24, Authorised, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Mektovi (updated)

binimetinib, Melanoma
Date of authorisation: 20/09/2018, , Revision: 7, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Roctavian (updated)

valoctocogene roxaparvovec,
Date of authorisation: 24/08/2022, , , , Revision: 3, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Pemazyre (updated)

pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021, , , , Revision: 6, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Vegzelma (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022, , , Revision: 4, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Tremelimumab AstraZeneca (updated)

Tremelimumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/02/2023, , Revision: 1, Authorised, Last updated: 11/09/2023
List item

Human medicine European public assessment report (EPAR): Benlysta (updated)

belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011, , Revision: 31, Authorised, Last updated: 11/09/2023
List item

Human medicine European public assessment report (EPAR): Natpar (updated)

parathyroid hormone, Hypoparathyroidism
Date of authorisation: 24/04/2017, , , , Revision: 16, Authorised, Last updated: 08/09/2023
List item

Human medicine European public assessment report (EPAR): Emgality (updated)

Galcanezumab, Migraine Disorders
Date of authorisation: 14/11/2018, , Revision: 10, Authorised, Last updated: 07/09/2023
List item

Human medicine European public assessment report (EPAR): Nepexto (updated)

etanercept, Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Arthritis, Psoriatic; Spondylarthropathies; Spondylitis, Ankylosing; Psoriasis
Date of authorisation: 20/05/2020, , , Revision: 10, Authorised, Last updated: 07/09/2023
List item

Human medicine European public assessment report (EPAR): Voxzogo (updated)

Vosoritide, Achondroplasia
Date of authorisation: 26/08/2021, , , Revision: 3, Authorised, Last updated: 06/09/2023
List item

Human medicine European public assessment report (EPAR): Ninlaro (updated)

ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016, , , , Revision: 16, Authorised, Last updated: 05/09/2023
List item

Human medicine European public assessment report (EPAR): Rekambys (updated)

rilpivirine, HIV Infections
Date of authorisation: 17/12/2020, , Revision: 8, Authorised, Last updated: 05/09/2023
List item

Human medicine European public assessment report (EPAR): Skyrizi (updated)

Risankizumab, Psoriasis; Arthritis, Psoriatic
Date of authorisation: 26/04/2019, , Revision: 16, Authorised, Last updated: 04/09/2023

Load more

611 results

Human medicine European public assessment report (EPAR): Revlimid (updated)

Human medicine European public assessment report (EPAR): Veyvondi (updated)

Human medicine European public assessment report (EPAR): Litfulo (updated)

Human medicine European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau) (updated)

Human medicine European public assessment report (EPAR): Jinarc (updated)

Human medicine European public assessment report (EPAR): GHRYVELIN (previously Macimorelin Aeterna Zentaris) (updated)

Human medicine European public assessment report (EPAR): Ranivisio (updated)

Human medicine European public assessment report (EPAR): Mepsevii (updated)

Human medicine European public assessment report (EPAR): Neparvis (updated)

Human medicine European public assessment report (EPAR): Xevudy (updated)

Human medicine European public assessment report (EPAR): Beovu (updated)

Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene) (updated)

Human medicine European public assessment report (EPAR): Mektovi (updated)

Human medicine European public assessment report (EPAR): Roctavian (updated)

Human medicine European public assessment report (EPAR): Pemazyre (updated)

Human medicine European public assessment report (EPAR): Vegzelma (updated)

Human medicine European public assessment report (EPAR): Tremelimumab AstraZeneca (updated)

Human medicine European public assessment report (EPAR): Benlysta (updated)

Human medicine European public assessment report (EPAR): Natpar (updated)

Human medicine European public assessment report (EPAR): Emgality (updated)

Human medicine European public assessment report (EPAR): Nepexto (updated)

Human medicine European public assessment report (EPAR): Voxzogo (updated)

Human medicine European public assessment report (EPAR): Ninlaro (updated)

Human medicine European public assessment report (EPAR): Rekambys (updated)

Human medicine European public assessment report (EPAR): Skyrizi (updated)